We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Greenlights Repatha as Second PCSK9 Inhibitor for LDL Cholesterol
FDA Greenlights Repatha as Second PCSK9 Inhibitor for LDL Cholesterol
The FDA approved Amgen’s Repatha late Thursday for some patients who are not able to control low-density lipoprotein cholesterol using standard treatment options, making it the second PCSK9 inhibitor to receive the agency’s blessing.